Suppr超能文献

过氧化物酶体疾病中的肾上腺功能不全:单机构病例系列。

Adrenal Insufficiency in Peroxisomal Disorders: A Single Institution Case Series.

机构信息

University of Alabama at Birmingham Marnix E. Heersink School of Medicine, Birmingham, Alabama, USA.

Department of Genetics, University of Alabama at Birmingham, Birmingham, Alabama, USA.

出版信息

Horm Res Paediatr. 2023;96(4):439-445. doi: 10.1159/000529126. Epub 2023 Jan 17.

Abstract

INTRODUCTION

There are two major categories of peroxisomal disorders (PDs): peroxisomal biogenesis disorders (PBDs) due to defects in peroxisomal (PEX) genes and deficiency of other peroxisomal enzymes (such as D-bifunctional enzyme deficiency due to HSD17B4). PDs are characterized by abnormal elevations of very-long-chain fatty acids (VLCFA). We aimed to evaluate the clinical phenotype of adrenal insufficiency in patients with PD and to assess any genotype-phenotype correlations with adrenal insufficiency.

CASE PRESENTATION

We performed a retrospective electronic medical record review at a single university medical center, of data over 12 years and identified 7 patients with PD. Of the 7 patients identified, 6 patients had a diagnosis of PBD and one had a single peroxisomal enzyme deficiency, HSD17B4. The average age of the patients at diagnosis were 0.61 ± 0.66 years. Four patients (66.7%) had primary adrenal insufficiency: 3, out of the 4, patients had elevated baseline ACTH. Three patients failed to have increased response after the Cortrosyn™ stimulation test. Three patients were on daily hydrocortisone replacement, and 1 patient was on stress-dose hydrocortisone only as needed. Specific genetic variant analysis revealed that all the 3 patients with PBD and adrenal insufficiency who were on steroid supplementation had the compound heterozygous pathogenic variant in exon 13 of PEX1 c.2097dupT (p.Ile700Tyrfs*42) and c.2528G>A (p.Gly843Asp), while the 1 patient with peroxisomal enzyme deficiency and adrenal insufficiency had compound heterozygous pathogenic variants in HSD17B4 c.1369A>T (p.Asn457Tyr) and c.1210 - 1G>A (splice acceptor). Two of these patients with PEX1 variants also required mineralocorticoid supplementation. The 3 PBD patients without adrenal insufficiency did not have a PEX1 variant.

DISCUSSION/CONCLUSION: Primary adrenal insufficiency is common in patients with PD. Based on our data, patients with the compound heterozygous PEX1 pathogenic variants of exon 13 (c.2097dupT and c.2528G>A) tend to have adrenal insufficiency. Aldosterone deficiency, though rare, can occur in PD.

摘要

介绍

过氧化物酶体病(PDs)有两大主要类别:过氧化物酶体生物发生障碍(PBD),这是由于过氧化物酶体(PEX)基因缺陷所致;过氧化物酶体酶缺乏(例如由于 HSD17B4 缺乏导致的 D-双功能酶缺乏)。PD 的特征是异常升高的极长链脂肪酸(VLCFA)。我们旨在评估 PD 患者肾上腺功能不全的临床表型,并评估与肾上腺功能不全相关的任何基因型-表型相关性。

病例介绍

我们在一家大学医学中心进行了一项回顾性电子病历审查,研究了超过 12 年的数据,共确定了 7 名 PD 患者。在确定的 7 名患者中,有 6 名患有 PBD,1 名患有单一过氧化物酶体酶缺乏症,即 HSD17B4。患者的平均诊断年龄为 0.61±0.66 岁。4 名患者(66.7%)存在原发性肾上腺功能不全:其中 3 名患者基线 ACTH 升高。3 名患者在 Cortrosyn™ 刺激试验后反应无增加。3 名患者每天接受氢化可的松替代治疗,1 名患者仅在需要时接受应激剂量氢化可的松治疗。特定的基因变异分析显示,所有 3 名接受类固醇补充治疗的 PBD 合并肾上腺功能不全患者均携带 PEX1 外显子 13 的复合杂合致病性变异 c.2097dupT(p.Ile700Tyrfs*42)和 c.2528G>A(p.Gly843Asp),而患有过氧化物酶体酶缺乏症和肾上腺功能不全的 1 名患者则携带 HSD17B4 c.1369A>T(p.Asn457Tyr)和 c.1210-1G>A(剪接受体)的复合杂合致病性变异。这 2 名携带 PEX1 变异的患者还需要补充盐皮质激素。无肾上腺功能不全的 3 名 PBD 患者没有 PEX1 变异。

讨论/结论:原发性肾上腺功能不全在 PD 患者中很常见。根据我们的数据,携带外显子 13 的复合杂合 PEX1 致病性变异(c.2097dupT 和 c.2528G>A)的患者倾向于发生肾上腺功能不全。尽管醛固酮缺乏症很少见,但也可能发生在 PD 中。

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验